Skip to main content

Table 4 Urinary and plasma L-FABP levels in patients in different stages of DKD

From: Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease

Groups Urinary L-FABP (μg/ml) Plasma L-FABP (μg/ml)
Median (IQR) Median (IQR)
DM patients with normoalbuminuria (n = 30) 5.9 (5.2, 7.8) 4.4 (2.9,11.3)
DKD patients with microalbuminuria (n = 30) 11.4 (6.7, 13.4)a 6.7 (3.4,11.4)
DKD patients with macroalbuminuria (n = 30) 18.8 (10.9, 23.4)a,b 8.6 (2.5,12.4)
  1. a P < 0.05 compared with the DM patients with normoalbuminuria (Kruskal-Wallis test)
  2. b P < 0.05 compared with the DKD patients with microalbuminuria (Kruskal-Wallis test)
  3. Abbreviations: IQR interquartile range, serum L-FABP serum liver-type fatty acid binding protein, urinary L-FABP urinary liver-type fatty acid binding protein